BIONOMICS LTD-ADR (BNOX) Stock Price, Quote, News and Overview

Company Profile

Bionomics Ltd is a AU-based company operating in Biotechnology industry. Bionomics Ltd is an Australia-based clinical-stage biopharmaceutical company. The firm is focused on development of novel drug candidates focused on the treatment of serious central nervous system disorders. The company is developing novel allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. The company is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Its α7 Receptor Positive Allosteric Modulators (PAMs) pipeline is targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. The Company’s CNS pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels.

Company Info

BIONOMICS LTD-ADR

200 Greenhill Road

Thebarton SOUTH AUSTRALIA AU

Employees: 8

Company Website: https://www.bionomics.com.au/

Investor Relations: https://www.bionomics.com.au/investor-centre/

Phone: 61881507400